Monday, April 17 

Partin B

Focus Group | Beigene Overview and BRUKINSA® (zanubrutinib) Clinical Update

8:00 AM - 9:15 AM

This presentation is designed to provide the audience with a brief introduction to BeiGene and its pipeline with a focus on the clinical development of zanubrutinib (Brukinsa ®), a bruton’s tyrosine kinase inhibitor.  This discussion is intended to be interactive in order to gain insights on clinical trial development (eg, head-to-head) and how compendia incorporation may impact decision-making for treatment.

Focus Group | Beigene Overview and BRUKINSA® (zanubrutinib) Clinical Update

9:30 AM - 10:45 AM

This presentation is designed to provide the audience with a brief introduction to BeiGene and its pipeline with a focus on the clinical development of zanubrutinib (Brukinsa ®), a bruton’s tyrosine kinase inhibitor.  This discussion is intended to be interactive in order to gain insights on clinical trial development (eg, head-to-head) and how compendia incorporation may impact decision-making for treatment.

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 8,500+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. 

Address: 1840 Gateway Drive 3rd Floor, San Mateo, CA 94404

Contact Phone Number: 877-828-5568

Contact Email: Torry Thomas

www.beigene.com